Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors

Press/Media

Period8 Nov 2022 → 9 Nov 2022

Media coverage

7

Media coverage

  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors; Kinimmune is developing KIN-102, a first-in-class immunostimulant that persists in treated tumors to minimize systemic sid
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletYahoo! News
    Country/TerritoryUnited States
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletYahoo! Finance
    Country/TerritoryUnited States
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletValdosta Daily Times
    Country/TerritoryGeorgia
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletBluefield Daily Telegraph
    Country/TerritoryUnited States
    Date9/11/22
    PersonsNabil Alhakamy
  • TitleKinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
    Media name/outletAcrofan
    Date8/11/22
    PersonsNabil Alhakamy